Genmab A/S Announces Top-Line Phase II Results for Ofatumumab Combined with Chemotherapy in Second Line Aggressive Lymphoma
COPENHAGEN, Denmark, Aug. 5, 2011 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN) announced today top-line results from a Phase II study of ofatumumab in combination with salvage chemotherapy to treat relapsed or refractory aggressive lymphoma, including Diffuse Large B-Cell Lymphoma (DLBCL).